Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Neuroendocrine 1

Interventions

Cisplatin 1041 Cyclophosphamide 974 Carboplatin 954 Radiotherapy 893 Bevacizumab 847 Gemcitabine 817 pembrolizumab 760 Paclitaxel 740 Docetaxel 734 Oxaliplatin 706 Capecitabine 650 Fluorouracil 564 Rituximab 559 Nivolumab 506 Dexamethasone 487 Etoposide 468 Doxorubicin 458 Irinotecan 442 Drug Therapy 402 Leucovorin 377 Cytarabine 342 Cetuximab 340 Lenalidomide 327 Trastuzumab 324 Pemetrexed 315 durvalumab 295 Filgrastim 287 Magnetic Resonance Spectroscopy 279 Temozolomide 275 Prednisone 274

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × OTHER × DLL3 protein, human × Clear all

NCT06893783 2026-04-13

DeLLight

Asan Medical Center

Phase 2 Recruiting

Carcinoma, Neuroendocrine

Data powered by HemOnc (CC BY 4.0) Colophon ⚡